Research map: Vonoprazan-Based Dual and Quadruple Therapy with Varying Duration for Helicobacter pylori Eradication: A Multicenter, Randomized Controlled Trial

Back to the article

Papers in this map

  1. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report · Peter Malfertheiner · 2022 · 1513 citations · Cited by this paper
  2. Machine learning-based drug susceptibility prediction from Candida genomic data · 2026 · Related
  3. Helicobacter pylori infection · Peter Malfertheiner · 2023 · 1193 citations · Cited by this paper
  4. Emergence of dalbavancin non-susceptible methicillin-resistant Staphylococcus epidermidis (MRSE) in a patient treated with dalbavancin prolonged therapy: Case report, therapeutic drug monitoring and genomic characterization · 2026 · Related
  5. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection · William D. Chey · 2024 · 393 citations · Cited by this paper
  6. Risk factors and outcome of extended-spectrum β-lactamase-producing Enterobacterales bacteraemia in high-risk neutropenic patients in haematology: A multicentre retrospective study · 2026 · Related
  7. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial · William D. Chey · 2022 · 311 citations · Cited by this paper
  8. An exploratory pharmacokinetic-pharmacodynamic analysis of ceftazidime-avibactam and various blood biomarkers in patients with hospital-acquired pneumonia or ventilator-associated pneumonia caused by Klebsiella pneumoniae · 2026 · Related
  9. 2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment · Liya Zhou · 2022 · 241 citations · Cited by this paper
  10. Vancomycin penetration into intra-abdominal compartments: Site concentration disparities and implications for dose optimization in gram-positive infections · 2026 · Related
  11. Optimal therapy for Helicobacter pylori infections · Emiko Rimbara · 2011 · 236 citations · Cited by this paper
  12. Optimizing the Meropenem Dosing Regimen in Neonates: A Dual-Centre Cohort Study · 2026 · Related
  13. Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial · Kai‐Feng Pan · 2024 · 113 citations · Cited by this paper
  14. A Novel blaTMB Allele Encoding a Functional Carbapenemase Associated with a Gamma-Mobile-Trio Island · 2026 · Related
  15. Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy · Haisheng Qian · 2022 · 101 citations · Cited by this paper
  16. Ecr positively regulates activity of the PhoQ/PhoP signalling system in Klebsiella pneumoniae · 2026 · Related
  17. Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg) · Olga P. Nyssen · 2021 · 98 citations · Cited by this paper
  18. High‐dose PPI‐amoxicillin dual therapy with or without bismuth for first‐line Helicobacter pylori therapy: A randomized trial · Lou Yu · 2019 · 76 citations · Cited by this paper
  19. Antibiotic resistance of Helicobacter pylori in Mainland China: A focus on geographic differences through systematic review and meta-analysis · Shuyan Zeng · 2024 · 47 citations · Cited by this paper
  20. Role of compliance in Helicobacter pylori eradication treatment: Results of the European Registry on H. pylori management · José María Huguet · 2024 · 46 citations · Cited by this paper
  21. Vonoprazan and amoxicillin dual therapy as the first‐line treatment of Helicobacter pylori infection: A systematic review and meta‐analysis · Ren‐Chun Du · 2023 · 42 citations · Cited by this paper
  22. Efficacy and Safety of Vonoprazan-Amoxicillin Dual Regimen With Varying Dose and Duration for Helicobacter pylori Eradication: A Multicenter, Prospective, Randomized Study · Xiang Peng · 2024 · 32 citations · Cited by this paper
  23. Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth‐containing quadruple therapy for Helicobacter pylori eradication in central China: A single‐center, prospective, open‐label, randomized‐controlled trial · Qiao‐Qiao Shao · 2022 · 26 citations · Cited by this paper
  24. Comparative Efficacy and Safety of Potassium-Competitive Acid Blocker-Based Dual, Triple, and Quadruple Regimens for First-Line Helicobacter pylori Infection Treatment: A Systematic Review and Network Meta-Analysis · Theodore Rokkas · 2024 · 25 citations · Cited by this paper
  25. Bismuth-Containing Quadruple Therapy for Helicobacter pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days · Yuming Ding · 2024 · 22 citations · Cited by this paper
  26. Artificial Intelligence‐Generated Patient Education Materials for Helicobacter pylori Infection: A Comparative Analysis · Shuyan Zeng · 2024 · 20 citations · Cited by this paper
  27. High‐dose dual therapy versus bismuth‐containing quadruple therapy for the eradication of Helicobacter pylori : A systematic review and meta‐analysis · Hui Wang · 2024 · 16 citations · Cited by this paper
  28. Efficacy of genotypic susceptibility‐guided tailored therapy for Helicobacter pylori infection: A systematic review and single arm meta‐analysis · Kaihao Lin · 2023 · 15 citations · Cited by this paper
  29. Comparative Efficacy and Safety of Potassium‐Competitive Acid Blockers and Proton Pump Inhibitors for First‐Line Helicobacter pylori Eradication Therapy: A Systematic Review and Network Meta‐Analysis · Mengling Ouyang · 2024 · 14 citations · Cited by this paper
  30. The Helicobacter pylori AI-clinician harnesses artificial intelligence to personalise H. pylori treatment recommendations · K M Higgins · 2025 · 13 citations · Cited by this paper
  31. Ten‐Day Versus 14‐Day Vonoprazan and Amoxicillin Dual Therapy for the Firstline Eradication of Helicobacter pylori Infection: A Multicenter, Randomized Controlled Trial · Zhiqiang Song · 2025 · 13 citations · Cited by this paper
  32. Optimal Duration of Bismuth‐Containing Quadruple Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta‐Analysis · Miao Duan · 2024 · 11 citations · Cited by this paper
  33. Ten‐day versus 14‐day vonoprazan‐amoxicillin high‐dose dual therapy for Helicobacter pylori eradication in China: A multicenter, open‐label, randomized study · Aiping Lin · 2024 · 11 citations · Cited by this paper
  34. It Is Time for a Paradigm Shift in Design, Execution, and Publishing of Comparative Helicobacter pylori Treatment Trials · David Yates Graham · 2023 · 10 citations · Cited by this paper
  35. Clarifying varied Helicobacter pylori eradication therapies: A comprehensive review · Xiaoqi Wu · 2024 · 8 citations · Cited by this paper
  36. Helicobacter pylori antimicrobial resistance and gene variants in Shandong Province · Zhijing Xue · 2025 · 8 citations · Cited by this paper
  37. Comparative Analysis of High-Dose Dual Therapies in First-Line Helicobacter pylori Eradication: An Inverse Probability of Treatment-Weighted Multicenter Study · Qingzhou Kong · 2026 · 4 citations · Cited by this paper
  38. Tailored Therapy Guided by Antibiotic Genotypic Resistances and CYP2C19 Polymorphisms Detected From Fecal Specimens for the First‐Line Helicobacter pylori Eradication: A Randomized Controlled Trial · Baojun Suo · 2025 · 3 citations · Cited by this paper
  39. Is 10-Day Vonoprazan With High-Dose Amoxicillin Dual Therapy Efficient for Eradicating Helicobacter pylori Infection in China? · Ren‐Chun Du · 2023 · 2 citations · Cited by this paper

Source: OpenAlex (CC0)